Explore RealPatient

Take a closer look at real-world evidence and clinical studies for CAR‑T therapy in patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL), follicular lymphoma (FL) and acute lymphoblastic leukemia (ALL).

Select your patient type to get started!

Disclaimer: This resource is an educational application only for worldwide healthcare professionals. It includes publicly available CAR‑T real-world evidence from large international and national registries and pivotal clinical trials. Reactive use only. Intended for HCPs.

Select an indication:

DLBCL ALL FL

Tisagenlecleucel ▼ is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of:¹
- Pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
- Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Reference: 1. Kymriah (tisagenlecluecel) [summary of product characteristics]. Nuremberg, Germany: Novartis Pharma GmbH; 2024.

5/24 434310